Dublin, May 23, 2023 (GLOBE NEWSWIRE) -- The "Glaucoma - Competitive Landscape, 2023" report has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive insights about 45+ companies and 50+ drugs in Glaucoma Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

According to the American Academy of Ophthalmology, glaucoma describes a group of conditions in which there is characteristic cupping of the optic disc with corresponding visual field defects due to retinal ganglion cell loss. It is a progressive condition and the most common cause of irreversible blindness worldwide. The two major categories of glaucoma are open-angle glaucoma and narrow-angle glaucoma/angle-closure glaucoma. The "angle" in both cases refers to the drainage angle inside the eye that controls the outflow of the watery fluid (aqueous) which is being produced inside the eye.

Open-angle glaucoma (OAG) is the most common form of the disease. The drainage angle formed by the cornea and iris remains open, but the trabecular meshwork is partially blocked. This causes pressure in the eye to increase gradually and damages the optic nerve.

It happens so slowly that the patient may lose vision before they are even aware of a problem, while in the case of narrow-angle glaucoma, the structure inside the eye that allows fluid to drain normally from the eye (called the drainage angle) becomes restricted. Narrow drainage angles in the eye increase the risk of the drainage angle that gets blocked, resulting in a significant increase in eye pressure and risk of vision loss. If this occurs, narrow-angle glaucoma is usually called angle-closure glaucoma.

Most people with glaucoma do not notice symptoms until they begin to lose eyesight. As glaucoma damages optic nerve fibers, small blind spots may begin to develop. These spots usually occur on the side or in the peripheral vision. Many people do not notice the blind spots until significant optic nerve damage has already happened. Blindness can result when the entire nerve is destroyed.

Given the asymptomatic development of early-stage glaucoma, the disease often progresses significantly before it is detected. For many years, it was believed that glaucoma affected primarily peripheral vision and central vision was left unharmed until very late in the disease.

Contrary to this dogma, research now shows that loss of peripheral vision is not an early indication of the disease, and that the full range of vision (peripheral and central) is often affected. Further, the visual field tests are not sensitive to early vision losses. By the time glaucoma is detected by a peripheral field test in many patients, more than half of the optic nerve fibers are damaged or have perished. Research is ongoing to perfect better tests for central vision that can detect the disease in earlier stages.

It is an inherited disease, meaning that if person have a family history of glaucoma, person are at increased risk. Additional risk factors include thin corneas or people with thinning of the optic nerve, general health conditions such as diabetes, obesity and circulatory problems, and other eye issues like extreme myopia and hyperopia.

There is no cure for glaucoma, but early treatment can often stop the damage and protect the vision. Doctors use a few different types of treatment for glaucoma, including medicines (usually eye drops), laser treatment, and surgery.

Report Highlights

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

Key Players

Key Products

For more information about this report visit https://www.researchandmarkets.com/r/ur4rd9

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.